Tsewang Tashi
( out of 61 reviews )

Tsewang Tashi, MD

Languages spoken: Tibetan, English, Mandarin Chinese, French, Hindi, Urdu

Clinical Locations

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
801-585-0236

VA - Building #14

Hematology/Oncology
801-582-1565

  • Dr. Tsewang Tashi joined the University of Utah faculty after completing his hematology/oncology fellowship in 2015. He received his medical degree from Chang Gung University, Taiwan, and completed his internal medicine residency both in Taiwan, and in the US from Creighton University Medical Center, Omaha, NE. Early in his career during fellowship, he has been involved in research with Dr. Josef Prchal on high altitude genetic adaptation, hypoxia signaling and molecular genetics of myeloproliferative neoplasms.

    His research and clinical interest lies in myeloid malignancies and currently sees and manages patients with myeloproliferative neoplasms, including systemic mastocytosis, and acute leukemias, both at the Huntsman Cancer Institute and serving the veterans at the George E. Whalen VA Medical Center in Salt Lake City. He established and currently leads the Mastocytosis Program at the Huntsman Cancer Hospital, which has been designated as Mastocytosis Center of Excellence. He also runs several clinical trials as the principal investigator in polycythemia vera, essential thrombocythemia, systemic mastocytosis and acute leukemia.

    At the VA Medical Center, he is one of the lead hematologists and cares for all the veterans with acute leukemias, myelodysplastic syndromes and myeloproliferative neoplasms that are referred to Salt Lake City VA from different parts of the Intermountain West. He also leads several research projects and conducts clinical trials.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    5.0 /5
    ( out of 61 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    August 04, 2023
    HUNTSMAN CANCER CENTER

    Superb

    July 27, 2023
    HUNTSMAN CANCER CENTER

    I was overwhelmed and exceedingly happy with his care and diagnosis ,him and his staff .I am hopeful and look forward to working with Dr. Tashi and his staff in resolving my condition. Thank You again.

    July 20, 2023
    HUNTSMAN CANCER CENTER

    Knowledgeable and patient. The best!

    July 14, 2023
    SOUTH JORDAN HEALTH CENTER

    Dr Tashi listened to my questions and concerns and took the time to explain the the answers to the questions.

    July 13, 2023
    SOUTH JORDAN HEALTH CENTER

    Dr.Tashi is Awsome I trust him with my care

    July 13, 2023
    SOUTH JORDAN HEALTH CENTER

    Dr. Tashi is always very kind and respectful. He listens to me and we plan my course of action together. I can tell that he really cares about me as a person and truly recommends the course of treatment and action that he feels is best for me and at the proper time.

    July 01, 2023
    SOUTH JORDAN HEALTH CENTER

    Dr. Tashi has an aura of calm respectfulness. He listens, really listens to my concerns, and takes the time to discuss them. He helps me look at my health in a reassuring positive view.

    May 25, 2023
    HUNTSMAN CANCER CENTER

    Great human being. Really professional

    May 18, 2023
    HUNTSMAN CANCER CENTER

    He is concerned about me as a person and makes sure I understand my cancer and treatment

    See More Patient Comments

  • Dr. Tsewang Tashi joined the University of Utah faculty after completing his hematology/oncology fellowship in 2015. He received his medical degree from Chang Gung University, Taiwan, and completed his internal medicine residency both in Taiwan, and in the US from Creighton University Medical Center, Omaha, NE. Early in his career during fellowship, he has been involved in research with Dr. Josef Prchal on high altitude genetic adaptation, hypoxia signaling and molecular genetics of myeloproliferative neoplasms.

    His research and clinical interest lies in myeloid malignancies and currently sees and manages patients with myeloproliferative neoplasms, including systemic mastocytosis, and acute leukemias, both at the Huntsman Cancer Institute and serving the veterans at the George E. Whalen VA Medical Center in Salt Lake City. He established and currently leads the Mastocytosis Program at the Huntsman Cancer Hospital, which has been designated as Mastocytosis Center of Excellence. He also runs several clinical trials as the principal investigator in polycythemia vera, essential thrombocythemia, systemic mastocytosis and acute leukemia.

    At the VA Medical Center, he is one of the lead hematologists and cares for all the veterans with acute leukemias, myelodysplastic syndromes and myeloproliferative neoplasms that are referred to Salt Lake City VA from different parts of the Intermountain West. He also leads several research projects and conducts clinical trials.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Hematology
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Graduate Training Master of Science in Clinical Investigation - University of Utah M.S.C.I
    Hematology/Oncology - University of Utah Fellow
    Residency Internal Medicine - Creighton University Resident
    Internal Medicine - Pingtung Christian Hospital Resident
    Internship Internal Medicine - MacKay Memorial Hospital Intern
    Medicine - Chang Gung University School of Medicine M.D.

    Selected Publications

    Journal Article

    1. Gotlib J, Castells M, Elberink HO, Siebenhaar F, Hartmann K, Broesby-Olsen S, George TI, Panse J, Alvarez-Twose I, Radia DH, Tashi T, Bulai Livideanu C, Sabato V, Heaney M, Van Daele P, Cerquozzi S, Dybedal I, Reiter A, Pongdee T, Barete S, Ustun C, Schwartz L, Ward BR, Schafhausen P, Vadas P, Bose P, DeAngelo DJ, Rein L, Vachhani P, Triggiani M, Bonadonna P, Rafferty M, Butt NM, Oh ST, Wortmann F, Ungerstedt J, Guilarte M, Taparia M, Kuykendall AT, Arana Yi C, Ogbogu P, Gaudy-Marqueste C, Mattsson M, Shomali W, Giannetti MP, Bidollari I, Lin HM, Sulllivan E, Mar B, Scherber R, Roche M, Akin C, Maurer M (2023). Avapritinib versus Placebo in Indolent Systemic Mastocytosis. NEJM Evid, 2(6), EVIDoa2200339. (Read full article)
    2. Tashi T, Yu J, Pandya S, Dieyi C, Scherber R, Parasuraman S (2023). Trends in overall mortality among US veterans with primary myelofibrosis. BMC Cancer, 23(1), 48. (Read full article)
    3. Chuah YY, Tashi T, Kuo CJ (2022). An unexpected cause of Cullen's sign: rupture of hepatocellular carcinoma. Br J Hosp Med (Lond), 83(11), 1. (Read full article)
    4. Verstovsek S, Mesa R, Mascarenhas J, Tashi T, Shih W, Sato T, Urbanski R, Zagrijtschuk O, Zimmerman C (2022). MPN-546 A Single-Arm Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in North American Adults With Essential Thrombocythemia. Clin Lymphoma Myeloma Leuk, 22 Suppl 2, S342-S343. (Read full article)
    5. Feusier JE, Arunachalam S, Tashi T, Baker MJ, VanSant-Webb C, Ferdig A, Welm BE, Rodriguez-Flores JL, Ours C, Jorde LB, Prchal JT, Mason CC (2021). Large-Scale Identification of Clonal Hematopoiesis and Mutations Recurrent in Blood Cancers. Blood Cancer Discov, 2(3), 226-237. (Read full article)
    6. Gangaraju R, Song J, Kim SJ, Tashi T, Reeves BN, Sundar KM, Thiagarajan P, Prchal JT (2019). Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia. Blood Adv, 4(6), 1115-1130. (Read full article)

    Review

    1. Tashi T, Deininger MW (2023). Management of Advanced Systemic Mastocytosis and Associated Myeloid Neoplasms. [Review]. Immunol Allergy Clin North Am, 43(4), 723-741. (Read full article)
    2. Tashi T (2022). Hematocrit, White Blood Cells, and Thrombotic Events in the Veteran Population With Polycythemia Vera. [Review]. Fed Pract, 39(Suppl 2), S43-S46. (Read full article)

    Case Report

    1. Chuah YY, Tashi T, Lee YY, Fu TY, Shih CA (2020). Enteropathy-associated T-cell Lymphoma (EATL) with intracranial metastasis : a rare and dismal condition. Acta Gastroenterol Belg, 83(1), 77-80. (Read full article)

    Editorial

    1. Song J, Tashi T, Prchal JT (2019). Editorial Comment on: Inhibition of Suicidal Erythrocyte Death by Chronic Hypoxia by Tang et al. (From: Tang F, Feng L, Li R, Wang W, Liu H, Yang Q, Ge R-L. High Alt Med Biol 2019;20:112-119; DOI: 10.1089/ham.2017.0159). High Alt Med Biol, 20(2), 120-121. (Read full article)

  • News & Podcasts

    Huntsman Cancer Institute News